RSV

The Biden administration said it will expand health care access, including mental health care, to students; depression reaches an all-time high in the United States; the FDA’s independent vaccine advisers are meeting to discuss the safety and effectiveness of a respiratory syncytial virus (RSV) vaccine.

A recent study compared hospitalizations and ages of children with respiratory syncytial virus (RSV) infection before the pandemic and afterwards.

An analysis of an urban population of children indicated that age was a strong predictor in the diagnosis of respiratory syncytial virus (RSV) and influenza.

A study found that not being infected with respiratory syncytial virus (RSV) in the first year of life was associated with a decreased risk of developing asthma in childhood.

A vaccine for adults 60 years and older was approved by the FDA for protection against respiratory syncytial virus, making it the first such vaccine to be approved worldwide.

Further epidemiologic studies on nonpharmaceutical interventions are warranted to assess their relationship with respiratory syncytial virus (RSV).

A nomogram that could assist physicians in predicting severe respiratory syncytial virus (RSV)–associated bronchiolitis early on was established and validated in a recent study.

A new study found that the MVA-BN-RSV vaccine was able to lower symptom scores and resulted in fewer confirmed RSV infections vs placebo.

Although the 28-day mortality for patients with respiratory failure did not differ between patients with and without respiratory syncytial virus (RSV), complications were more common in those with RSV.

Long-term temporal and spatial trends, as well as changes, can be estimated using hospital admission data when the burden on health care systems is increased.

Patients who were admitted to the hospital for respiratory syncytial virus (RSV) had a higher risk of a complex hospital course and had higher rates of respiratory support compared with patients admitted for influenza.

A recent study found the mortality rate for patients hospitalized for respiratory syncytial virus (RSV) to be 6.6%, with approximately 25% of hospitalized patients requiring admission to the intensive care unit.

A new study has found that respiratory syncytial virus (RSV) infections were more frequent and severe compared with influenza A/B in older adults.

Payers are looking to roll back on paperwork requirements for prior authorization (PA); CMS and Medicare Advantage (MA) insurers battle over new regulations; Johnson & Johnson (J&J) falls behind Pfizer and GSK for vaccine approval.

The incidence of respiratory syncytial virus (RSV)–positive acute respiratory infection (ARI) was found to be significant in the period prior to the COVID-19 pandemic in older adults.

Former NBA star Magic Johnson has partnered with GSK to educate the public about this virus, specifically in seniors and those at high-risk for contracting a severe form of RSV.

Associated hospitalization burden could be 2.2 times higher in older adults with respiratory syncytial virus (RSV) than was previously estimated, according to a recent study.

A pediatric shot for respiratory syncytial virus (RSV) may not be covered as a free routine vaccine; hospitals fail to comply with payment transparency rules; the fate of abortion pills is in the hands of conservative judges

Children and families living in low-income neighborhoods have the highest rate of respiratory syncytial virus (RSV) hospitalizations, according to researchers.

Patients with respiratory syncytial virus infection (RSV) were also more likely to have underlying chronic respiratory conditions and other comorbidities, according to a recent study looking at people hospitalized in ICUs.